Somatostatin-dopamine chimeric analogs

Details Somatostatin-dopamine chimeric analogs Somatostatin-dopamine chimeric analogs

2002-06-07

2009-08-25

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

8 to 10 amino acid residues in defined sequence

C530S327000, C530S329000, C530S330000, C530S311000, C530S345000

Reexamination Certificate

active

07579435

ABSTRACT:
Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8β-ergolinglmethylthioacetyl-D-Phe-c-(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2.

REFERENCES:
patent: 2589978 (1952-03-01), Stoll
patent: 2619488 (1952-11-01), Stoll
patent: 3966941 (1976-06-01), Semonsky et al.
patent: 4108855 (1978-08-01), Mago nee Karacsony et al.
patent: 4871717 (1989-10-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5043341 (1991-08-01), Cohen et al.
patent: 5145837 (1992-09-01), Feyen et al.
patent: 5411966 (1995-05-01), Sauer et al.
patent: 5621133 (1997-04-01), DeNinno et al.
patent: 5753618 (1998-05-01), Cavanak et al.
patent: 5925618 (1999-07-01), Baumbach et al.
patent: 6025193 (2000-02-01), Weiss
patent: 6066616 (2000-05-01), Cavanak et al.
patent: 6117427 (2000-09-01), Hill et al.
patent: 6221870 (2001-04-01), Pfaeffli et al.
patent: 6468767 (2002-10-01), Weinshank et al.
patent: 618 187 (1962-05-01), None
patent: 140 044 (1980-02-01), None
patent: 0 126 968 (1988-12-01), None
patent: 959261 (1964-05-01), None
patent: 1004310 (1965-09-01), None
patent: 2 103 603 (1983-02-01), None
patent: 2 112 382 (1983-07-01), None
patent: 6408237 (1965-01-01), None
patent: 91/11447 (1991-08-01), None
patent: 94/14806 (1994-07-01), None
patent: 94/17104 (1994-08-01), None
Losse, Guenter, European Journal of Medicinal Chemistry 14(4), 325-8, 1979.
Torsello (Endocrinology 143 (5) 1968, 2002).
Hoffman, A.J. et al., “Synthesis and LSD-like Discriminative Stimulus Properties in a Series of N(6)-Alkyl Norlysergic Acid N, N-Diethylamide Derivatives,” J. Med. Chem., 1985, 28(9):1252-1255.
Rocheville, M. et al., “Receptors for Dopamine and Somatostatin: Formulation of Hetero-Oligomers with Enhanced Functional Activity,” Science, 2000, 288(5643):154-157.
Walzel, B. et al., “Mehcanism of alkaloid cyclopeptide synthesis in the ergot fungusClaviceps purpurea,” Chemistry and Biology, 1997, 4:223-230.
Krepelka, J. et al., “Some esters of N-(D-6-methyl-8-ergolin-1-ylmethyl)-carbamic acid,” Collection Czechoslov. Chem. Commun., 1977, 42:1886-1889.
Mantegani, S. et al., “Synthesis and antihypertensive activity of 2,4-dioxoimidazolidin-1-yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives,” Il Farmaco, 1998, 53:293-304.
Miyagi, M. et al., “Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats,” Biol. Pharm. Bull., 1996, 19:1210-1213.
Saveanu, A. et al., “A chimeric somatostatin-dopamine molecule, BIM-23A387 has enhanced potency in suppressing GH and PRL secretion in acromegaly,” ENEA 2002 Conference, Munich, Germany, Sep. 12-14, 2002, OC-2.4, p. 40, Abstract (XP-002306950).
Saveanu, A. et al., “Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells,” J. Clin. Endo. & Metabl., 2002, 87:5545-5552.
Stoll, A. et al., “Synthesis of 6-Methyl-8-oxyisoergoline (I) and Attempts to Dehydrogenate Same to 6-Methyl-ergolin-8-one,” 28thReport on Ergot Alkaloids, Helvetica Chimica Acta., 1952, 35(152-153):1249-1258.
Fioravanti et al., “Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis”, Drugs Exp. Clin. Res., 1995, 21:97-103. (Abstract only).
Ishibashi, M., et al., “Inhibition of growth of human small cell lung cancer by bromocriptine”, Cancer Res., 1994, 54:3442-3446.
Jaquet, P., “Evidence for dopamine agonists in the treatment of acromegaly,” J. Endo., 1997, 155:S59-S60.
Taylor, J. E., et al., “In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue”, Biochem. Biophys. Res. Comm., 1988, 153:81-86.
Terenius, L., “Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors”, Eur. J. Pharmacol., 1976, 38:211-3. (Abstract only).
Yamashita, K. et al., “Inhibitory effect of somatostatin on Helicobacter pylori proliferation in vitro”, 1998, Gastroenterology, 115:1123-1130.
Colao, A. et al., “Growth hormone and prolactin excess,” The Lancet, 1998, 352:1455-1461.
Freda, P. et al., “Clinical Review 110: Diagnosis and treatment of pituitary tumors,” J. Clin. Endo. Metab., 1999, 84(11):3859-3866.
Jaquet, P. et al., “Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas,” J. Clin. Endo. Metab., 1999, 84(9):3268-3276.
Maheshwari, H. et al., “Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma,” J. Clin. Endo. Metab., 2000, 85(9):3409-3416.
Figueroa, F. E. et al., “Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis”, Br. J. Rheum., 1997, 36:1022-1023.
Gabor, F. et al., “Drug-protein conjugates: haptenation of 1-methyl-10a-methozydihydrolysergol and 5-bromonicotinic acid to albumin for the production of epitope-specific monoclonal antibodies against nicergoline”, J. Pharm. Sci., 1995, 84:1120-1125.
Temperilli, A. et al., “Anti-hypertensive activity of ergolinyl-ureido and thioureido derivatives”, Eur. J. Med. Chem., 1988, 23:77-81.
English language Abstract for International Application No. WO 00/04018 published Jan. 27, 2000.

Affiliated with

Also associated with

Rating

Somatostatin-dopamine chimeric analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Somatostatin-dopamine chimeric analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin-dopamine chimeric analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4078799